Domperidone-induced elevation of serum prolactin levels and immune response in multiple sclerosis.
Increasing systemic prolactin levels improves remyelination and neuronal survival in animal models of Multiple Sclerosis (MS), but it has been suggested that this therapeutic strategy may also increase inflammatory responses, and potentially harm patients. We analyzed serum prolactin and cytokine, chemokine and growth factor levels in sera from MS patients enrolled in two clinical trials who were treated with domperidone, a generic drug that increases systemic prolactin levels. In patients treated with domperidone, molecule levels changed little during follow up, while prolactin levels increased several-fold. We found no significant association between prolactin levels and radiological or clinical outcome.
['Koch|Marcus W|MW|', 'Liu|Wei-Qiao|WQ|', 'Camara-Lemarroy|Carlos|C|', 'Zhang|Yunyan|Y|', 'Pike|G Bruce|GB|', 'Metz|Luanne|L|', 'Yong|V Wee|VW|']
D000328:Adult D015415:Biomarkers D004294:Domperidone D018492:Dopamine Antagonists D005260:Female D005500:Follow-Up Studies D006801:Humans D007111:Immunity, Cellular D018836:Inflammation Mediators D008297:Male D008875:Middle Aged D020529:Multiple Sclerosis, Relapsing-Remitting D010865:Pilot Projects D011388:Prolactin
Prolactin Multiple sclerosis CNS Neuroinflammation